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Upstream transcription factor 1 (USF1) allelic variants significantly influence future risk of cardiovascular
disease and overall mortality in females. We investigated sex-specific effects of USF1 gene allelic variants on
serum indices of lipoprotein metabolism, early markers of asymptomatic atherosclerosis and their changes
during six years of follow-up. In addition, we investigated the cis-regulatory role of these USF1 variants in
artery wall tissues in Caucasians. In the Cardiovascular Risk in Young Finns Study, 1,608 participants (56%
women, aged 31.9 6 4.9) with lipids and cIMT data were included. For functional study, whole genome
mRNA expression profiling was performed in 91 histologically classified atherosclerotic samples. In
females, serum total, LDL cholesterol and apoB levels increased gradually according to USF1 rs2516839
genotypes TT,CT,CC and rs1556259AA,AG,GGaswell as according toUSF1H3 (GCCCGG) copy
number 0, 1, 2. Furthermore, the carriers of minor alleles of rs2516839 (C) and rs1556259 (G) of USF1
gene had decreased USF1 expression in atherosclerotic plaques (P 5 0.028 and 0.08, respectively) as
compared to non-carriers. The genetic variation in USF1 influence USF1 transcript expression in advanced
atherosclerosis and regulates levels and metabolism of circulating apoB and apoB-containing lipoprotein
particles in sex-dependent manner, but is not a major determinant of early markers of atherosclerosis.
T
he upstream transcription factor 1 (USF1) is a ubiquitously expressed transcription factor regulating tran-
scription ofmany genes from lipid and glucosemetabolism pathways1. TheUSF1 contains a helix-loop-helix
motif, which binds an E-box motif in the promoter region of its target genes and leads to transcription
activation and/or enhanced gene expression2. There are very few data regarding USF1 transcript levels in human
tissues. In two studies of adipose tissue, USF1 transcript levels did not differ in relation to USF1 alleles1,3.
According to our knowledge USF1 expression or the effect of its genetic variation on gene expression in artery
wall has not been reported in any previous investigations.
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The USF1 gene is localized on chromosome 1q23, consists of 11
exons and extends to 6.73 kb (National Centre for Biotechnology
(NCBI), gene ID: 7391). Initially this gene was localized in 19984
and then identified as the first familial combined hyperlipidemia
(FCHL) gene in rare Finnish pedigree with multiple affected indivi-
duals having a greatly increased risk for cardiovascular disease
(CVD)1. This finding was rapidly replicated in Mexican families5.
Since then USF1 and its genetic variation has also been associated
with themetabolic syndrome and type II diabetes6–8. In earlier studies
we showed that some of the USF1 gene variants are associated with
the surface area of atherosclerotic lesions measured directly from
coronaries after autopsy in men9 and reported that two USF1 SNPs
(rs3737787 and rs2516838) and USF1 haplotype are associated with
carotid intima-media thickness (cIMT)10.
In a study with two large prospective Finnish cohorts, the effect of
USF1 allelic variants on CVD risk and overall mortality was seen in
females only11. Given the differences in CVD event rate, life-expect-
ancy and mortality between men and women, the gender-specific
effects of USF1 are of obvious interest. Another study performed
using mouse models showed that over-expression of human USF1
in mice influenced metabolic trait phenotypes in sex-dependent
manner12. There are also earlier existing sex-specific results concern-
ing USF1 polymorphisms and lipids parameters1,13,14. Any difference
in the USF1 gene effects on CVD risk factors or lipoprotein metabo-
lisms between men and women may provide further valuable insight
into the biology of the increased susceptibility of women to CVDs.
These previous results give justified rationale for additional sex-spe-
cific analyses.
Early indices of atherosclerosis namely cIMT, carotid artery dis-
tensibility (Cdist), and brachial artery flow-mediated dilatation
(FMD) have all been shown to predict future cardiovascular
events15–20. The previous reports of USF1 alleles on these markers
are inconclusive in the sex-specific effects10.
In the present study, we used the ongoing prospective Cardio-
vascular Risk in Young Finns Study (YFS) follow-up (2001 and
2007) and Tampere Vascular Study (TVS) materials21–23 in order to
investigate the effects of USF1 gene allelic variants on serum indices
of lipoprotein metabolism, early markers of asymptomatic athero-
sclerosis and their changes during six years follow-up separately in
men and women. Since the direct contribution of these USF1 gene
variants on the gene function in artery wall tissues has not been
previously tested we also investigated the cis-regulatory role of
studied USF1 alleles in artery wall tissues.
Results
Characteristics of YFS and TVS subjects. Table 1 shows the
characteristics of 1608 study subjects in YFS in 2001. Overall, men
had more unfavorable cardiovascular risk factor profiles compared
with women. In addition, men had higher cIMT values, lower
brachial artery FMD, as well as lower Cdist.
Supplementary Table 1 shows the clinical characteristics of 91
patients in TVS. Case and control subjects had similar risk factor
profiles with an exception that the cases had lower BMI than the
controls.
USF1 polymorphisms and haplotypes in YFS. The USF1 allele and
haplotype frequencies together with the six studied SNPs are shown
in Table 2. A total of five common USF1 haplotypes were identified,
accounting for 97.9% of all variation in theUSF1 gene. There were no
statistically significant differences in haplotype frequencies between
men and women (data not shown). All USF1 genotype distributions
were in accordance with the Hardy-Weinberg equilibrium for the
entire population and the subgroups divided by sex (data not shown).
USF1 polymorphisms, haplotypes and their sex interactions with
serum lipid and apolipoprotein measurements. There were
statistically significant genotype (rs2516839, rs1556259) and
haplotype (H3) differences by sex interaction in relation to serum
total- and LDL-cholesterol as well as apoB levels in 2007 (Table 3). In
females, serum total-, LDL-cholesterol and apoB levels increased
gradually according to USF1 rs2516839 genotype TT , TC , CC
and rs1556259 AA , AG , GG as well as according to USF1
haplotype 3 (H3, GCCCGG) copy number 0 , 1 , 2, constantly
in both 2001 and 2007 (Table 3). There was a similar trend for both
years 2001 and 2007 for the effect of theseUSF1 polymorphisms and
haplotypes, although the trend tended to be statistically stronger and
consistent in 2007 at aged 30–45, when the subjects were an average
6-year older than in 2001 (aged 24–39 years) (Table 3).
There were also other associations between studied USF1 poly-
morphisms, haplotypes and some other classical lipid markers in
2001 and in 2007 (see Supplementary Tables 2–5), but these associa-
tions were not as consistent as they were for total-, LDL-cholesterol
and apoB levels. Therefore, this study was focused on more detailed
second stage analyses (by using proton-NMR spectroscopy) on
mainly to those lipoprotein subclass measures with most consistent
genetic associations in a sex-specific manner.
In females, both rs2516839 and rs1556259 genotypes associated
significantly with the longitudinal change from 2001 to 2007 in LDL
cholesterol values (P 5 0.044 and P 5 0.009, respectively, repeated-
measurement RANCOVA main effect for genotype, age and BMI at
2001 as covariates). Similarly, the USF1 rs1556259 genotypes assoc-
iated significantly with the longitudinal change in total cholesterol
levels (P 5 0.021). The females carrying the haplotype 3 had signifi-
cantly higher total- and LDL cholesterol concentrations throughout
the six-year follow-up period compared with noncarriers of this
haplotype (P5 0.008 and P5 0.006, respectively). These effects were
sex-specific and were not found in males.
USF1 polymorphisms, haplotypes and lipid metabolism at
subclass level in women. To avoid unnecessary multiple testing
the three most significant genetic markers associated with classical
lipids (results from above), rs2516839, rs1556259 and haplotype H3
were selected for more detailed and focused two stage statistical
analysis in relation to selected indices of cholesterol and lipid
metabolism over different lipoprotein subclasses in women. We
investigated the effects of USF1 genotypes and haplotypes over
serum lipoprotein subclass cholesterol fractions (total cholesterol,
cholesterol ester, and free cholesterol when available) and total
Table 1 | Characteristics of the Cardiovascular Risk in Young Finns
Study population in 2001
Variable men women
No. of subjects 706 902
Age, years 31.9 6 5.0 31.9 6 4.9
Body mass index, kg/m2 25.6 6 3.8 24.2 6 4.3
Systolic blood pressure, mm Hg 129 6 14 116 6 12
Diastolic blood pressure, mm Hg 75 6 9 71 6 9
Total cholesterol, mmol/L 5.22 6 0.98 5.03 6 0.87
LDL cholesterol, mmol/L 3.42 6 0.88 3.13 6 0.75
HDL cholesterol, mmol/L 1.17 6 0.27 1.40 6 0.30
Triglycerides, mmol/L 1.42 6 0.82 1.13 6 0.53
Apolipoprotein A1, g/L 1.40 6 0.21 1.56 6 0.26
Apolipoprotein B, g/L 1.12 6 0.26 0.99 6 0.23
Glucose, mmol/L 5.21 6 0.87 4.90 6 0.72
Insulin, mU/L 7.46 6 5.88 7.61 6 5.63
CRP, mg/L 1.43 6 3.42 2.18 6 4.33
Daily smoking, % 46.6 36.9
IMT 2001, mm 0.59 6 0.10 0.57 6 0.09
FMD 2001, % 6.83 6 4.05 8.75 6 4.49
Cdist 2001, %/10 mmHg 2.02 6 0.67 2.33 6 0.77
Values are mean 6 SD or percentage of subjects. All comparisons (t tests) between men and
women P , 0.001, except for age and insulin (P . 0.6).
www.nature.com/scientificreports
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lipid concentrations in women. We show the associations between
the above parameters and three genetic markers in women in 2007 in
Figure 1. There were significant genotype and haplotype effects on
the total cholesterol level of small VLDL, total lipid level of very small
VLDL, total cholesterol and lipid levels and free cholesterol level of
IDL, and all the three subclasses of LDL in 2007 (Figure 1 and
Supplementary Table 6). These results were replicable and there
was a similar trend for both follow-up years 2001 and 2007 for the
effect of these polymorphisms and haplotypes, although the trend
tended to be statistically stronger in 2007 at aged 30–45 (Figure 1 and
Supplementary Table 6) than in 2001 (aged 24–39 years) (Supple-
mentary Table 7). These genotype and haplotype effects are consis-
tent with the results from the classical lipid measurements.
USF1 polymorphisms, haplotypes, and markers of subclinical
atherosclerosis. In females, the USF1 rs2516839 genotypes asso-
ciated significantly with the cIMT in longitudinal analysis (P 5
0.012, repeated-measurement ANOVA main effect for genotype).
Those with CC genotype had highest cIMT in both 2001 and 2007.
However, this effect disappeared after adjusting for classical risk
factors for CAD and again was not seen in males. We did not find
any significant differences in cIMT, brachial artery FMD, or Cdist
between other USF1 SNP genotype groups, haplotype groups in
longitudinal analyses either among men or among women (data
not shown).
USF1 expression in the atherosclerotic tissue. We compared the
USF1 mRNA expression examined with GWEA between athero-
sclerotic plaque samples and non-atherosclerotic internal thoracic
arteries, as well as USF1 expression between different vessel types.
The USF1 expression level (isoform 2) was significantly lower in
atherosclerotic plaque specimens (N 5 68) than in control tissue
(N 5 23, P 5 0.049, Mann-Whitney U test). The USF1 gene
expression was significantly reduced in the carotid plaques (N 5
29, P 5 0.05, Mann-Whitney U test), but not in the femoral
plaques (N 5 24, P 5 0.10, Mann-Whitney U test) and aorta (N
5 15, P 5 0.32, Mann-Whitney U test) although they followed the
same trend. There was no difference in the USF1 expression between
women and men.
Relation ofUSF1 polymorphisms and haplotypes to expression of
USF1 and known USF1 target genes. Sixty-nine subjects (aged 40–
91 years, males 71%) had complete data concerning the six USF1
SNPs and gene expression data. The six studied USF1 SNPs formed
five major haplotypes. These haplotypes accounted for 97% of all
variation in the USF1 gene. Because no interaction between the
SNP or haplotype and subject status (case vs. control) was found
to be significant, we proceeded to analyze the effect of the
haplotypes or SNPs within all samples in order to increase the
statistical power. We found that minor homozygotes (CC and GG
carriers) of both SNPs, rs2516839 and rs1556259, had lower USF1
expression than the T allele and A allele carriers (P 5 0.028 and P 5
0.08, respectively, Mann-Whitney U test). The GCCCGG haplotype
was the only haplotype carrying both the C allele of the rs2516839
polymorphism and G allele of the rs1556259 polymorphism. The
carriers of the above haplotype tended to have lower USF1
expression than the non-carriers (P 5 0.06, Mann-Whitney U test).
Of the 47 known USF1 target genes24,25, the chemokine (C-X-C
motif) receptor 4 (CXCR4) was up-regulated in CC carriers of
rs2516839 (P 5 0.013, Mann-Whitney U test) and haplotype
GCCCGG carriers (P 5 0.04, Mann-Whitney U test). The hemo-
globin beta (HBB) was down-regulated in CC carriers of rs2516839
(P 5 0.01, Mann-Whitney U test) and haplotype GCCCGG carriers
(P 5 0.05, Mann-Whitney U test).
Discussion
We found a female-specific association of USF1 variants and haplo-
type with serum levels of both total lipids and lipoprotein subclasses
in YFS. Furthermore, we found the association of theseUSF1 variants
and haplotype with USF1 expression in the carotid artery plaque in
TVS. To our knowledge, this study is the first showing that theUSF1
gene expression is down-regulated in atherosclerotic lesions and
USF1 variants (SNP rs2516839 and rs1556259) are associated with
the down-regulation. The results of the present study imply that
USF1 variants are likely to have causal effects due to the genetic
influence of the variants on gene expression.
The biological importance of the USF1 gene has been implied in
previous studies, which were mostly conducted on study subjects
with specific selection criteria, such as presence of FCHL1,5, CVD14,
diabetes7,26, metabolic syndrome26 or obesity27. There were little
direct data from in vivo studies as to USF1 transcript levels in human
tissues. In two studies of adipose tissue, USF1 transcript levels did not
differ in relation to USF1 alleles1,3. One study showed clear sex-
related differences in trait expression in mouse models and the gene
expression patterns were also notably different between the sexes12.
Our results are consistent with studies done using female mice, in
which the enrichment for metabolism-related categories was
demonstrated12.
The association between the USF1 variants and lipid levels are
inconsistent with previous publications. Our findings are in agree-
ment with a population based data set from the Finns that the minor
allele (C) of rs2516839 was associated with increased lipid values
among study subjects with cardiovascular disease11. Contradictory
to studies where the common allele T of rs2516839 associated with a
more unfavorable risk profile6,26,28,29, the minor allele C of rs2516839
of our sample associated with increased LDL cholesterol levels. The
major alleles of rs2516839 and rs1556259 were associated with
Table 2 | Details of the loci and haplotypes in the USF1 gene
Usf1s1 Usf1s8 Usf1-4530 Usf1s7 Usf1s9 Usf1-81
dbSNP ID rs3737787 rs2516838 rs10908821 rs2516839 rs1556259 rs2774276
Allele G/A C/G C/G T/C A/G C/G
MAF 0.357 0.271 0.136 0.371 0.131 0.233
haplotype Frequency (%)
H1 A C C T A G 35.4
H2 G G C T A G 26.3
H3 G C C C G G 13.2
H4 G C G C A C 13.1
H5 G C C C A C 10.5
MAF, minor allele frequency. The minor allele of each SNP is underlined.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4650 | DOI: 10.1038/srep04650 3
Ta
bl
e
3
|T
he
as
so
ci
at
io
n
of
se
ru
m
to
ta
l-
an
d
LD
L-
ch
ol
es
te
ro
l
an
d
ap
ol
ip
op
ro
te
in
B
le
ve
ls
w
ith
U
SF
1
ge
no
ty
pe
s
an
d
ha
pl
ot
yp
e
3
(H
3)
ac
co
rd
in
g
to
ge
nd
er
an
d
fo
llo
w
-u
p
ye
ar
.
Th
e
C
ar
di
ov
as
cu
la
rR
is
k
in
Yo
un
g
Fi
nn
s
St
ud
y
Fo
llo
w
-u
p
Ye
ar
SN
P
or
ha
pl
ot
yp
e
G
en
ot
yp
eo
r
co
py
of
ha
pl
ot
yp
e
N
(w
om
en
)
M
ea
n
6
SD
P
N
(m
en
)
M
ea
n
6
SD
P
N
(a
ll)
M
ea
n
6
SD
P
To
ta
lc
ho
le
ste
ro
l(
m
m
ol
/L
)
20
01
rs
25
16
83
9
TT
34
9
5.
01
6
0.
85
0.
67
28
2
5.
27
6
1.
00
0.
53
6
63
1
5.
12
6
0.
93
0.
82
TC
41
9
5.
04
6
0.
89
32
6
5.
18
6
0.
94
74
5
5.
10
6
0.
91
C
C
12
3
5.
09
6
0.
90
96
5.
22
6
1.
05
21
9
5.
14
6
0.
97
rs
15
56
25
9
A
A
66
5
5.
00
6
0.
86
0.
04
1
53
6
5.
23
6
0.
99
0.
84
8
12
01
5.
10
6
0.
93
0.
33
5
A
G
21
8
5.
10
6
0.
90
15
0
5.
18
6
0.
95
36
8
5.
13
6
0.
92
G
G
12
5.
57
6
1.
03
13
5.
19
6
0.
65
25
5.
37
6
0.
86
H
3
0
67
0
5.
00
6
0.
86
0.
04
7
54
3
5.
23
6
0.
99
0.
88
2
12
13
5.
10
6
0.
93
0.
32
8
1
21
7
5.
11
6
0.
90
14
8
5.
18
6
0.
96
36
5
5.
14
6
0.
92
2
15
5.
47
6
0.
97
15
5.
22
6
0.
62
30
5.
34
6
0.
81
20
07
rs
25
16
83
9
TT
34
9
4.
81
6
0.
80
0
.0
1
3
28
2
5.
20
6
0.
91
0.
39
2
63
1
4.
98
6
0.
87
0.
25
4
TC
41
9
4.
93
6
0.
79
32
6
5.
10
6
0.
89
74
5
5.
01
6
0.
84
C
C
12
3
5.
03
6
0.
87
96
5.
18
6
0.
90
21
9
5.
10
6
0.
89
rs
15
56
25
9
A
A
66
5
4.
85
6
0.
80
0
.0
0
9
53
6
5.
16
6
0.
91
0.
44
3
12
01
4.
99
6
0.
86
0.
18
2
A
G
21
8
5.
02
6
0.
82
15
0
5.
07
6
0.
85
36
8
5.
04
6
0.
83
G
G
12
5.
22
6
0.
97
13
5.
31
6
0.
55
25
5.
26
6
0.
77
H
3
0
67
0
4.
85
6
0.
80
0
.0
0
6
54
3
5.
17
6
0.
92
0.
33
6
12
13
4.
99
6
0.
87
0.
12
9
1
21
7
5.
02
6
0.
82
14
8
5.
07
6
0.
85
36
5
5.
04
6
0.
83
2
15
5.
23
6
0.
93
15
5.
34
6
0.
63
30
5.
29
6
0.
78
LD
Lc
ho
le
ste
ro
l(
m
m
ol
/L
)
20
01
rs
25
16
83
9
TT
34
9
3.
10
6
0.
76
0.
57
28
2
3.
45
6
0.
88
0.
56
7
63
1
3.
26
6
0.
84
0.
64
4
TC
41
9
3.
14
6
0.
73
32
6
3.
38
6
0.
85
74
5
3.
24
6
0.
79
C
C
12
3
3.
18
6
0.
78
96
3.
46
6
0.
96
21
9
3.
30
6
0.
87
rs
15
56
25
9
A
A
66
5
3.
11
6
0.
74
0
.0
1
1
53
6
3.
42
6
0.
88
0.
80
9
12
01
3.
25
6
0.
82
0.
12
8
A
G
21
8
3.
18
6
0.
76
15
0
3.
37
6
0.
90
36
8
3.
26
6
0.
83
G
G
12
3.
72
6
0.
88
13
3.
46
6
0.
79
25
3.
58
6
0.
83
H
3
0
67
0
3.
10
6
0.
73
0
.0
1
5
54
3
3.
43
6
0.
87
0.
71
6
12
13
3.
25
6
0.
82
0.
11
4
1
21
7
3.
19
6
0.
77
14
8
3.
37
6
0.
90
36
5
3.
26
6
0.
83
2
15
3.
61
6
0.
85
15
3.
51
6
0.
75
30
3.
56
6
0.
79
20
07
rs
25
16
83
9
TT
34
9
2.
85
6
0.
69
0
.0
0
2
28
2
3.
30
6
0.
80
0.
61
9
63
1
3.
05
6
0.
77
0.
06
8
TC
41
9
2.
96
6
0.
69
32
6
3.
24
6
0.
79
74
5
3.
08
6
0.
75
C
C
12
3
3.
10
6
0.
73
96
3.
31
6
0.
79
21
9
3.
19
6
0.
76
rs
15
56
25
9
A
A
66
5
2.
89
6
0.
68
0
.0
0
3
53
6
3.
27
6
0.
79
0.
27
6
12
01
3.
06
6
0.
76
0.
02
6
A
G
21
8
3.
05
6
0.
74
15
0
3.
22
6
0.
78
36
8
3.
12
6
0.
76
G
G
12
3.
30
6
0.
75
13
3.
57
6
0.
56
25
3.
44
6
0.
66
H
3
0
67
0
2.
89
6
0.
68
0
.0
0
3
54
3
3.
28
6
0.
80
0.
16
0
12
13
3.
07
6
0.
76
0.
02
2
1
21
7
3.
05
6
0.
74
14
8
3.
21
6
0.
78
36
5
3.
12
6
0.
76
2
15
3.
26
6
0.
75
15
3.
60
6
0.
64
30
3.
43
6
0.
71
A
po
lip
op
ro
te
in
B
(g
/L
)
20
01
rs
25
16
83
9
TT
34
9
0.
97
6
0.
23
0.
46
9
28
2
1.
12
6
0.
26
0.
92
4
63
1
1.
04
6
0.
26
0.
88
6
TC
41
9
0.
99
6
0.
23
32
6
1.
12
6
0.
24
74
5
1.
05
6
0.
24
C
C
12
3
1.
00
6
0.
23
96
1.
11
6
0.
27
21
9
1.
05
6
0.
25
rs
15
56
25
9
A
A
66
5
0.
98
6
0.
23
0.
30
9
53
6
1.
12
6
0.
26
0.
80
4
12
01
1.
04
6
0.
25
0.
35
2
A
G
21
8
0.
99
6
0.
24
15
0
1.
11
6
0.
24
36
8
1.
04
6
0.
25
G
G
12
1.
08
6
0.
25
13
1.
15
6
0.
21
25
1.
11
6
0.
23
H
3
0
67
0
0.
98
6
0.
23
0.
33
54
3
1.
12
6
0.
26
0.
78
1
12
13
1.
04
6
0.
25
0.
36
1
21
7
1.
00
6
0.
24
14
8
1.
11
6
0.
25
36
5
1.
04
6
0.
25
2
15
1.
06
6
0.
23
15
1.
16
6
0.
20
30
1.
11
6
0.
22
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4650 | DOI: 10.1038/srep04650 4
increased triglycerides and lower HDL cholesterol levels in the
Australian subjects with documented CAD28. The common allele
of the SNP associated with increased cholesterol and triglyceride
levels also in Utah families ascertained for type 2 diabetes mellitus29.
In another study, the CC genotype of SNP rs2516839 showed sug-
gestive association with decreased risk of metabolic syndrome in
Chinese hospital cases26. The minor homozygotes of rs1556259
had lowest LDL cholesterol level in women6. However, in these stud-
ies, the effect of USF1 was more pronounced in subjects already
diagnosed with CAD, FCHL, diabetes and metabolic syndrome. In
our study, the subjects are healthy young Finns which might explain
the lack of association of USF1 SNPs markers with lipid measures.
The discrepancies regarding the minor allele of rs2516839 and
rs1556259 in lipid levels in our study and other studies may be
explained with the complicated interactions between USF1 variants
and age (healthy and quite young in our study), sex, other genes, and
environmental factors. At the moment there were no functional
studies available that could explain these differences. Thus, further
functional studies of the effects of rs2516839 as well as other USF1
variants are needed to solve this discrepancy.
We also found an association between USF1 rs2516839 and cIMT
during six years follow-up in female although this effect disappeared
after adjusting for classical risk factors of CAD. The carriers of minor
allele of rs2516839 had higher mean cIMT values. This is in agree-
ment with the same allele carriers having higher LDL cholesterol
levels. The sex-related differences observed in our study are in line
with previous studies reporting that USF1 variants associated with
CVD11,30 and mortality11 among women. Contrary to the previous
studies1,9,14, our female subjects showed stronger associations than
males, and the effects of rs2516839 and rs1556259 were significant
only in the female subset. In a single study that included only males9,
the USF1 risk allele identified was different from the risk allele
segregating in our study. In 700 Finnish middle-aged men (the
Helsinki Sudden Death Study, HSDS)9, the risk for advanced athero-
sclerotic plaques, calcification, and sudden cardiac death was assoc-
iated with the common allele of rs2516839, whereas in the present
study the minor allele of rs2516839, was associated with elevated
LDL cholesterol level and cIMT. Interestingly, in female U.S.
Whites with CAD, the rare allele was associated with risk, whereas
in males the common allele of rs3737787 conferred risk13. Consistent
with human studies, the sex specificity was also observed in a mouse
model12. The molecular mechanisms underlying our sex-specific
allelic difference are unknown. The hormonal factorsmay contribute
to the differences.
USF1 is a ubiquitous transcription factor that regulates the
expression of many genes involved in lipid metabolism, immune
response, endothelial function and aging. It could contribute to the
development of atherosclerosis and its complications through many
different pathways. In our study, we did not find significant USF1
genotype difference of gene expression in most of the previously
identified USF1 target genes except CXCR4 andHBB. Previous stud-
ies have reported that the CXCR4 levels are increased in patients with
heart failure31 and thatmyocardial CXCR4 levels are increased 5-fold
inmyocardium subjected to ischemic injury, compared with levels in
non-injuredmyocardium in the same heart32. Other studies have also
reported that the hemoglobin levels are independently associated
with increased risk for new cardiac events33,34. Further studies are
needed for understanding the mechanism behind our findings
between the USF1 variants and the up-regulated CXCR4 and
down-regulated HBB expression.
We did not find any significant difference of USF1 expression
between male and female in TVS study. These expression results in
TVS samples should be interpreted with caution due to small sample
size and low number of women, and thus possible lack of statistical
power. It would be interesting to repeat the observation with larger
numbers of subjects.T
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In conclusion, our findings support the role of USF1 variants and
haplotypes in lipid metabolism in gender-dependent manner and
establish a new association of USF1 variants with gene expression
in carotid arteries. Further research is needed on the associations
between the USF1 SNPs, haplotypes and cardiovascular end points.
Methods
Study subjects. The YFS is an ongoing five-center, prospective cohort study of
atherosclerosis risk factors underlying cardiovascular disease in children and young
adults. Details of the study design have been presented elsewhere22. In short, the study
was launched in 1980 and included 3,596 children and adolescents aged 3 to 18 years.
In 2001, a total of 2,283 participants aged 24–39 years were re-examined, and in 2007,
we examined 2,204 subjects aged 30–45 years. The present study included 1,608
subjects for whom complete data on lipids and cIMT in both year 2001 and 2007 were
available (female, N 5 902; male, N 5 706).
All subjects gave a written informed consent in 2001 and 2007. The study was
approved by the local ethics committees. Themethods were carried out in accordance
with the approved guidelines. More detailed information about the cohorts and the
follow-up procedures can be found in the cohort descriptions of the Project (http://
vanha.med.utu.fi/cardio/youngfinnsstudy/index.html).
Clinical characteristics. Weight and height were measured, and body mass index
(BMI) was calculated. Blood pressure was measured with a random zero
sphygmomanometer. The average of three measurements was used in the analyses.
Information on smoking, alcohol consumption, and physical activity was obtained
with a questionnaire. Those smoking on daily basis were defined as smokers.
Biochemical analyses. In 2001 and 2007, venous samples were taken after the subject
had fasted for 12 hours. Serum total cholesterol levels were measured by the
enzymatic cholesterol esterase – cholesterol oxidase method (Cholesterol reagent,
Olympus, Ireland). The same reagent was used for estimating HDL-cholesterol levels
after precipitation of apoB-containing lipoproteins with dextran sulfate-Mg21. LDL-
cholesterol was estimated by the Friedewald formula35 in subjects with triglycerides
levels ,4.0 mmol/L. The serum triglyceride concentration was assayed using the
enzymatic glycerol kinase-glycerol phosphate oxidase method (Triglyceride reagent,
Olympus). Serum glucose concentration was determined by the enzymatic
hexokinase method (Glucose reagent, Olympus). Apolipoprotein A1 (ApoA1) and B
were analysed immunoturbidometrically (Orion Diagnostica, Espoo, Finland). The
above mentioned analyses were all performed on an AU400-analyzer (Olympus,
Japan). Serum insulin concentration was determined by a microparticle enzyme
immunoassay (IMx insulin reagent, Abbott Diagnostics, USA) on an IMx instrument
(Abbott). The method has been described in more detail elsewhere36. Fasting plasma
high sensitive C-reactive protein (CRP) concentrations were analyzed by means of
latex turbidometric immunoassay (Wako Chemicals GmbH, Neuss, Germany).
Measurements of carotid artery IMT and brachial artery FMD. Ultrasound
examinations were performed using Sequoia 512 ultrasound mainframes (Acuson,
CA, USA) with 13.0 MHz linear array transducers, as described previously in detail37.
Figure 1 | Forest plots for the associations of USF1 polymorphisms (rs2516839, rs1556259,), haplotype 3 and serum lipoprotein subclass cholesterol
fractions (total cholesterol, cholesterol ester, and free cholesterol when available) and total lipid concentrations in women in 2007. Plots show the
association estimates (b) and 95% confidence intervals for the lipoprotein subclass levels presented as bars. C, total cholesterol; CE, cholesterol ester; FC,
free cholesterol; IDL, intermediate-density lipoprotein; HDL, high-density lipoprotein; L, total lipids; LDL, low-density lipoprotein; VLDL, very-low-
density lipoprotein.
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In short, to measure carotid IMT, the image was focused on the posterior (far) wall of
the left carotid artery. A minimum of four measurements of the common carotid far
wall was taken approximately 10 mm proximal to the bifurcation to derive mean and
maximal cIMT values. To evaluate brachial artery FMD, the left brachial artery
diameter was measured both at rest and during reactive hyperemia, as described
previously38. The vessel diameter in scans after reactive hyperemia was expressed as a
percentage relative to the resting scan value (%). To assess carotid artery elasticity
indices, the best–quality cardiac cycle was selected from the images and manually
analyzed to measure systolic and diastolic common carotid diameters. The carotid
distensibility (Cdist) was then calculated using ultrasound and concomitant brachial
blood pressure measurements, as described previously39. These analyses were
performed for YFS subjects in 2001 and in 2007.
Lipoprotein subclass analysis by proton-NMR spectroscopy. Concentrations of
lipoprotein subclasses as well as their cholesterol content were analyzed by proton
NMR spectroscopy in native serum samples as described previously40. These serum
subclasses were classified as follows: chylomicrons and extremely large VLDL
particles (average particle diameter at least 75 nm); five different VLDL subclasses:
very large VLDL (average particle diameter of 64.0 nm), large VLDL (53.5 nm),
medium VLDL (44.5 nm), small VLDL (36.8 nm), and very small VLDL (31.3 nm);
intermediate-density lipoprotein (IDL) (28.6 nm); three LDL subclasses: large LDL
(25.5 nm), medium LDL (23.0 nm), and small LDL (18.7 nm); and four HDL
subclasses: very large HDL (14.3 nm), large HDL (12.1 nm), medium HDL
(10.9 nm), and small HDL (8.7 nm)40. This methodology has recently been applied in
various extensive epidemiological and genetics studies41–43 with consistent findings
with respect to lipoprotein genetics44.
DNA extraction and genotyping of the USF1 polymorphisms. For subjects in YFS,
DNA was extracted from peripheral blood leukocytes using a commercially available
kit (Qiagen Inc, Hilden, Germany) in 2001. DNA samples were genotyped by
employing the 59 nuclease assay for allelic discrimination, using the ABI Prism
7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). PCR
reaction containing genomicDNA, 23TaqManUniversal PCRMasterMix, 900 nM
of each primer, and 200 nM of each probe was performed in 384-well plates
according to standard protocol in a total volume of 5 ml. Water controls and known
control samples were run in parallel with unknown samples. After cycling, end-point
fluorescence was measured, and USF1 genotypes (rs3737787, rs2073658, rs2516838,
rs10908821, rs2516839, rs1556259, rs2774279, rs2774276) calling was carried out by
the allelic discrimination analysis module. The eight SNPs were selected from the
HapMap database and SeattleSNPs database and previous publications. Two of the
SNPs selected in the preliminary phase, rs2073658 and rs2774279, were left out from
further analyses because they were in almost complete linkage disequilibrium with
rs3737787 and rs2516838, respectively. The linkage between rs2516838 and
rs2516839 was weak (r2 5 0.22).
In TVS, genomic DNA was extracted from peripheral blood leukocytes using
QIAampH DNA Blood Minikit and automated biorobot M48 extraction (Qiagen,
Hilden, Germany).Whole genome genotyping using the Illumina HumanHap660W-
Quad BeadChip (Illumina, Inc., San Diego, CA, USA) was carried out from TVS
samples according to manufactures recommendation as described in detail in sup-
plementary methods.
Vascular sample collection, RNA isolation, expression analysis and quality
control.The atherosclerotic plaque samples (male, N5 46; female, N5 22) and non-
atherosclerotic control samples (male, N 5 20; female, N 5 3, left internal thoracic
arteries, LITA) used in this study were collected as part of ongoing TVS21,23,45–47. The
study was approved by the Ethics Committee of Tampere University Hospital, and
the study subjects gave their informed consent. The clinical characteristics of TVS
subjects are shown in supplementary Table 1 and details of sample collection in
supplementary methods. All open vascular surgical procedures were performed at the
Division of Vascular Surgery and control samples collected at Heart Center, Tampere
University Hospital. The study was approved by the Ethics Committee of Tampere
University Hospital, and the study subjects gave their informed consent. The vascular
samples were classified according to recommendations of American Heart
Association (AHA)48 by experienced pathologist. All the internal thoracic artery
samples that were used as controls were verified to be microscopically healthy.
In TVS, vascular endarterectomy samples constituting the intima and inner media
from carotid, femoral and aortic regions were obtained. RNA isolation, genome-wide
expression analysis, RNA quality control of these atherosclerotic plaque and non-
atherosclerotic control tissue samples, was performed as previously described21,23,45–47
(see details in supplementary methods).
Statistical analyses. Statistical analyses were performed using the PASWStatistics 18.
Non–normally distributed triglycerides, insulin, and CRP concentrations were log10-
transformed before the analyses, but the results are expressed as crude. Data are
presented as mean 6 SD, unless otherwise stated. The characteristics of the study
subjects were compared with the t test for continuous variables. Categorical variables
were compared with the x2–test, which was also used to test the genotype frequencies
under Hardy–Weinberg equilibrium. In order to study the possible association
between USF1 gene polymorphisms and risk factors and subclinical markers of
atherosclerosis, we applied analysis of variance (ANOVA) and analysis of covariance
(ANCOVA). The non-parametric Mann-Whitney U test was used for comparison of
gene expression between atherosclerotic and control tissues, as well as between
different genotype and haplotype groups.
Frequencies of themost common haplotypes and themost probable haplotypes for
each study subject were determined using the PHASE program (Version 2.0.2)49. To
study the effect of haplotypes, we divided the population into carriers (one copy and
two copies of haplotype) and non-carriers or into three groups with 0, 1, 2 copy of
haplotype.
To avoid redundant multiple testing in YFS, the statistical analyses were done in
separate stages. We first did sex-by-genotype (or -by-haplotype) interaction analyses
in relation to conventional lipids and apolipoproteins by two-way ANOVA. If sig-
nificant interaction was found, we stratified the subjects by sex in further analyses. As
hypothesized, sex-specific interactions in relation to serum total- and LDL-choles-
terol and apoB were found and the USF1 genotype/haplotype related results were
statistically significant in women only. In the second stage of statistical analysis, we
investigated in women the effects of USF1 genotypes and haplotypes over serum
lipoprotein subclass cholesterol fractions (total cholesterol, cholesterol ester, and free
cholesterol when available) and total lipid concentrations.
The subclass measures were inverse normal transformed to achieve approximate
normality. Associations of USF1 SNPs and haplotypes with lipoprotein subclass
measures were tested using univariate additive geneticmodel. Statistical analyses were
performed using the R Statistical package v. 2.11.1 (http://www.r-project.org).
P–value , 0.05 was considered nominally significant. For Table 3, we calculated
false discovery rate (FDR) multiple correction calculations in the women strata
assuming there were 18 independent tests (2 SNPs and 1 haplotype, 2 time points, 3
lipid measures), using the calculation below and assuming an FDR value of , 0.05
was acceptable.
FDR 5 p-value 3 number of tests/p – value rank
Therefore, P # 0.015 in the women strata were considered statistically significant
after correcting for multiple testing.
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